NME Sponsors Followed PDUFA V’s “Program” To Advisory Committee Success In 2013
Executive Summary
New review model’s elements, including the mid-cycle communication and late-cycle meeting, helped make for a smoother advisory committee process for Janssen’s Olysio and Bayer’s Adempas. The sponsors and FDA review staff were able to reach agreement on labeling and other review issues in advance, narrowing the scope of matters requiring vetting by the expert panels.
You may also be interested in...
FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?
Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.
FDA Needs More Time To Review Sugammadex Inspection Report, Cancels Advisory Committee
Merck’s anesthesia reversal agent, which was deemed “not approvable” in 2008, faces another setback as FDA cancels its July 18 advisory committee meeting to allow more time to review clinical trial site inspection data.
Learning From Its Successes? FDA Wants Feedback On All First-Cycle Actions For Assessment Program
Interviews with all sponsors that receive a first-cycle action, approvals as well as other outcomes, under PDUFA V’s new NME and original BLA review program will help FDA assess the program’s success.